September 9-11, 2025 | Boston, MA www.bispecific.com REGISTER BY FRIDAY, JUNE, 13 & SAVE UP TO \$900

WELCOME

16th Annual World Bispecific Summit

Enhance VEGFxPD1 Mechanistic Understanding, Target Selectivity & Binding Affinity to Supercharge the Discovery & Development of Bispecifics in Oncology & Autoimmune Diseases

Expert Speakers Include:



Raymond Perez Head, Immunomodulatory Agents Global Project



Kara Olsen Fellow Scientist Regeneron





John Mascola Chief Scientific Officer ModeX Therapeutics

Annelise Vuidepot

Chief Technology

Officer



Zymeworks

Director, Immunology

Alexey Berezhnov

Tony Arulanandam Chief Executive Officer Synaptimmune Therapeutics

Lead Partner

invenra







Exhibition Partners: BIOCYTOGEN P BIOINTRON Crevative Biolats Sinicoya OmniAb



Welcome to the 16th World Bispecific Summit

In the world of bispecifics, no recent development is generating as much excitement as PD-1xVEGF and PD-L1xVEGF bispecifics, catalyzed by groundbreaking data from Ivonescimab, which reduced the risk of disease by 49% compared to Keytruda. While bispecific developers work to understand the mechanistic basis of this target combination, strides to find novel target pairings, and diversify development into autoimmune indications, 2025 stands as a pivotal year to shape current and future bispecific development.

The 16th World Bispecific Summit returns as industry's longest-running and most comprehensive event, devoted exclusively to the design, development, and translation of bispecific and multispecific therapeutics. Bringing together the likes of Regeneron, Sanofi, Novartis, Immunocore, Zymeworks, and more to help you unlock the success behind PD-1xVEGF bispecifics with our brand-new Pre-Conference PD-1xVEGF Mechanism Day, understand how to develop bispecifics for autoimmune diseases and delve in to impoved target specificity to reduce toxicities.

As your complete guide to everything bispecifics, this is your opportunity to pick apart the bispecific and target biology and overcome translational bottlenecks to advance more bispecifics to best-in-class drugs.

Along with 100+ of your peers in R&D, biology, and translational sciences from large pharma and biotech you will be joining a room full of people on the same journey of supercharging the next generation of bispecific drugs.

We look forward to welcoming you back to Boston this September.

Your 2025 Agenda Highlights



Join trailblazing researchers reimagining bispecific and tetraspecific T cell engagers to drive broader and more durable anti-tumor responses, even in the face of tumor heterogeneity and antigen escape



Gain insights from cutting-edge preclinical and clinical studies demonstrating how multispecific and companion TCE approaches blend immune and targeted therapies to maximize synapse signaling, optimize activation thresholds, and overcome resistance in solid and hematologic cancers



Explore how advanced engineering, including tetraspecific formats and masking technologies, are reshaping multispecific drug design to improve tissue specificity, reduce off-target toxicity, and enhance therapeutic precision in oncology



Uncover the power of refined antibody affinity and epitope targeting to enable conditional immune activation. Learn how these tunable design elements are being leveraged to deliver safer, more selective T cell and cytokine responses with improved translational outcomes

immune cell engagers **AbbVie**

Clear presentations, diverse topics, great setting for networking after the speed dates and lovely organization, food and venue

Merus



Engage in cross-functional discussions with immunologists, translational scientists, and bispecific developers to explore how dual-targeting strategies, novel mechanisms. and conditional activation are advancing safer and more effective autoimmune therapies



September 9-11, 2025 | Boston, MA

What our speakers

Enjoyed the high level of

engagement on a breadth

of topics spanning phases

of discovery to late stage

clinical development of

have to say:

Bispecific

WELCOME





Your Expert Speakers

Bispecific Summit September 9-11, 2025 | Boston, MA









Chief Technology Officer **Aethon Therapeutics**



John Mascola Chief Scientific Officer **ModeX Therapeutics**



Bradley Delaney Business Development Specialist Nona Biosciences

Rob Tighe Head, Preclinical Sciences & Translation **Ottimo Pharma**



Donald Shaffer Head, ImmunoOncology & **Cell Therapy** Sanofi



3

Tony Arulanandam Chief Executive Officer Synaptimmune Therapeutics

Rajkumar Ganesan



Center





Alexey Berezhnoy Director, Immunology **Zymeworks**



World Bispecific Pre-Conference Summit September 9-11, 2025 | Boston, MA **PD-1xVEGF** Mechanism Day Tuesday, September 9 Morning Coffee and Check-in 8.30 **Nimish Gera** Co-Founder & Vice **Chair's Opening Remarks** 9.25 President, Biologics & Scientific **Mythic Therapeutics** Learning the Success Behind PD1 x VEGF & PD-L1 x VEGF by Dissecting the Target Biology & Mechanism of Action Overviewing the Biology of the Targets PD1-VEGF & Their Interactions at a 9 30 Cellular & Molecular Level to Help Tailor the Bispecific Format • Examining the biology of the combination target PD1-VEGF and how the design and Gordon Freeman Professor cellular interactions can be used to tailor the Bispecific format Dana-Farber Cancer • Understanding how the initial design of PD1-VEGF was chosen by understanding the Institute biology of the molecule - looking at data for this with different Bispecifics Exploring by the specific combination of antibodies used in PD1-VEGF and why this combination was chosen whilst considering their biology 10.00 Investigating How Simultaneous Targeting of VEGF, PD-L1 & CTLA4 Reshapes the Tumor Microenvironment to Outline Modes of Action & Safety **Considerations For Your Bispecifics** · Exploring the immunomodulatory effects of VEGF targeting that synergize with known **Mohamed-Reda** Benmebarek antiangiogenic effects and inform safety considerations for its targeting **CRTA** Postdoctoral Dissecting the multimodal mechanism induced by multitargeting strategy to understand Fellow how simultaneous targeting of axes present of diverse cell types in the tumor **National Cancer** microenvironment can alter the cytokine landscape and ultimately rewire key effector Institute and suppressive cell types: considerations of efficacy and safety Assessing the practicality of using bispecifics for membrane-bound and soluble targets: Exploring the potential benefits and challenges of how multitargeting strategies can best tackle the underlying immunobiology 10.30 Morning Break & Speed Networking The ideal opportunity to get face-to-face with many of the brightest minds working in the bispecific field and introduce yourself to the attendees that you would like to have more in-depth conversations with. Leveraging Valuable Preclinical, Clinical, & Safety Data to Gain Key Learnings for PD-L1 x **VEGF & Apply These Understandings to Address Current Mechanistic Gaps** OTP-01 (Jankistomig), A Unique Dual Paratopic Antibody that Bifunctionally 11.30 Inhibits PD-1 and VEGFR2 • Structural differentiation: Unlike head-to-tail bispecifics, OTP-01 is a standard effectornull IgG1 that possesses a unique dual-paratopic Fab with overlapping binding sites that **Rob Tighe** co-engage PD-1 and VEGFR2 in a single arm Head, Preclinical Functional differentiation: Leveraging a standard IgG1 backbone, OTP-01 potently Sciences & Translation and cooperatively engages both targets to enhance tumor biodistribution, while **Ottimo Pharma** simultaneously neutralizing - VEGF-A/C/D signalling to optimally remodel the TME and curb resistance Clinical trajectory: OTP-01 is now in IND-enabling studies, with IND submission targeted for late 2025

4

hansonwade

PARTNER WITH US

REGISTER YOUR PLACE

EXPERT SPEAKERS

Pre-Conference PD-1xVEGF Mechanism Day Tuesday, September 9



Bridging Bench & Bedside for PD-1 x VEGF & PD-L1 x VEGF Bispecifics: Translational Strategy, Format Optimization & Combination Approaches

As PD-1 x VEGF and PD-L1 x VEGF bispecifics progress through preclinical and early clinical pipelines, developers are challenged to refine therapeutic design, clarify mechanisms of synergy, and anticipate translational hurdles. This roundtable will bring together expert voices and engaged attendees to explore what it will take to successfully advance the bispecifics and other bispecifics using similar logic to clinical impact.

- · How can target biology guide decisions on bispecific format, affinity tuning, and spatial delivery?
- · What insights and programs help us define meaningful biomarkers and pharmacodynamic readouts?
- · How can we rationally combine these bispecifics with other immunotherapies or modalities like ADCs and cytokines?
- What are the biggest translational blind spots (e.g. preclinical models) holding back predictive development?
- · How do we de-risk safety in multitargeting strategies, especially when soluble and membrane-bound targets are involved?





5

12.00

12.45 Lunch Break

Expanding beyond PD1 x VEGF to PD1/PDL1 Targeted Bispecifics – Advancing Targeted Cytokine Strategies with Bispecific Constructs

| | Donald Shaffer | 1.45 | Designing Targeted Cytokines: Preclinical Lessons from PD-1/PD-L1- Directed IL-15 Bispecifics | | | |
|----------|--|---|--|--|--|--|
| | ImmunoOncology & | | SAR445710 (KD033) a trans-presented high affinity IL-15 vs SAR445877 (KD050) a cis- presented reduced affinity IL-15. | | | |
| | Cell Therapy Sanofi | | Reviewing pre-clinical in vitro and in vivo pharmacology data | | | |
| | Sanon | | • Exploring broader design considerations for targeted cytokines in oncology and beyond | | | |
| | - | 215 | From Bench to Bedside: Early Phase Clinical Insights Into SAR445710 (KD033) and SAR445877 (KD050), Distinct Cytokines Targeting PDL1 or PD1 | | | |
| | Head, Immunomodulatory | | Reviewing Phase I safety, pharmacokinetic, pharmacodynamic, and preliminary efficacy data | | | |
| | Agents Global Project Sanofi | | Understanding the translational relevance of preclinical findings in clinical settings Looking to future directions for PD-1/PD-L1-targeting cytokines in immune-oncology pipelines | | | |
| | Nimish Gera Co-Founder & Vice President, Biologics & | 2.45 | Chair's Closing Remarks | | | |
| | Scientific Mythic Therapeutics | | | | | |
| | | 3.00 | End of Pre-Conference PD-1xVEGF Mechanism Day | | | |
| | | | sh quality of appakara, proper aiza far | | | |
| | | | In quality of speakers, proper size for | | | |
| | net | networking and discussions, effective audio and | | | | |
| | рі | rojecti | ion settings, and excellent location | | | |
| CurieBio | | | | | | |
| | | | | | | |





Conference Day One Wednesday, September 10



6



Norld Bispecific

September 9-11, 2025 | Boston, MA

Conference Day One Wednesday, September 10

1.00



Inflammation by Inhibiting IL-4Ra and IL-33 Pathways Exploring how ZW1528 binds to both IL-4Ra and IL-33, and mediates potent blockade of IL-4, IL-13 and IL-33 enabling a broad and simultaneous inhibition of key inflammatory Alexey Berezhnov pathwavs Director, Immunology Demonstrating translational relevance as ZW1528 inhibits Type 2 and non-Type 2 **Zymeworks** responses in vitro in primary immune cells of COPD patients, effectively modulating diverse immune pathways across patient subtypes Investigating how ZW1528 demonstrates IgG-like PK and biomarkers of target blockade in the NHP, supporting clinical viability through favourable pharmacokinetics and validated target engagement Conditionally active 41BB Costimulatory CD19 x CD20 T Cell engager 1.30 designed for deeper and durable responses and minimal cytokine release for Autoimmune Diseases • Costimulation built in CD19 x CD20 T Cell Engager (TCE) to achieve CAR-T like **Tony Arulanandam** Chief Executive Officer potency, immune reset and efficacy for Autoimmune diseases Synaptimmune Conditional Activation of TCE only in presence of antigen engagement overcomes **Therapeutics** cytokine release syndrome associated with conventional TCE's Shows increased potency and efficacy in the humanized SLE mouse model compared to benchmark TCE BlinatumomabTM and other CD19 and CD20 TCE's in development for Autoimmune Diseases 2.00 Innovating Biologics Discovery using the NonaHCAbFx Platform • The limitations of camelid nanobodies in bispecifics and the advantages of fully human **Bradley Delaney** HCAbs from Harbour Mice® Business Development A novel function-based screening platform for identifying CD19-targeting HCAbs using a Specialist CAR-Jurkat reporter system Nona Biosciences Discovery of fully human CD19 TCEs with superior cytotoxicity compared to reference molecules 2.15 Afternoon Break & Poster Session This is an informal session to help you connect with your peers in a relaxed atmosphere and forge new and beneficial relationships. With an audience of bispecific experts eager to hear the latest innovations and positive movement, you will have the opportunity to display a poster presenting your own work. Additionally, you will have the chance to review others' posters displaying cutting-edge work from drug discovery right through to exciting clinical trial updates.

ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway



7



Conference Day One Wednesday, September 10

optimizing design parameters to enhance efficacy while managing safety.

Hayretin

Associate

Director

Yumerefendi

Novartis AG



AGENDA

PARTNER WITH US

How do different bispecific modalities (e.g. T-cell engagers, costimulatory bispecifics, ADCs) influence target selection strategy? · How do you balance the therapeutic window by assessing target expression across tumor versus normal tissue to mitigate toxicity? Kara Olsen Joachim Fellow Scientist **Kiemle Kallee** Regeneron

Senior Medical Director, Drug Safety Liason SOTIO

Officer Lyvgen

Jieyi Wang Founder & Chief Executive **Biopharma**

8

selected target

Nimish Gera

Biologics &

Scientific

Mythic

Co-Founder &

Therapeutics

Vice President,

3.15

4.15 Session Reserved for BSP Pharmaceuticals

Strategic Target Selection to Optimize Bispecific Design, Format & Functionality

This panel will examine how aligning target biology, mechanism of action, and bispecific format is critical to therapeutic success. Experts will explore strategies for selecting and validating novel targets, addressing tumor heterogeneity, and

 How do you determine whether a target's biology aligns with the intended mechanism of action of your bispecific construct? · What are the key molecular design considerations? Looking at considerations, such as affinity, format, and valency for a

 How can we better predict and manage unexpected biology that arises from targeting a molecule in a specific disease context? What approaches are most effective for validating novel targets, particularly in solid tumors with heterogeneous expression?

Panel Discussion: Strategic Target Selection for Optimizing Bispecific Design & Function



4.45 End of Conference Day One

REGISTER YOUR PLACE

C +1 617 455 4188 info@hansonwade.com 🕀 www.bispecific.com in World Bispecific Forum

hansonwade

Conference Day Two Thursday, September 11

| | | 8.00 | Morning Coffee & Check-in |
|----|--|--------|--|
| | Aung Naing Professor The University of Texas MD Anderson Cancer Center | 8.55 | Chair's Opening Remarks |
| En | hancing T-Cell Pre | cision | & Activation: Strategies to Overcome Tumor Heterogeneity & Maximize Bispecific Efficacy |
| 7 | Kevin Carbajal Associate Director, Scientific Strategy Research Inceptor Bio | 9.00 | Supercharging T Cell Engagers: Expanding Immune Activation Beyond Traditional Bispecific Design Unlocking innate immunity by introducing a novel approach to load innate immune cells with a T cell engager receptor, enabling engagement by existing T cell engagers in vivo From T cell engager to multi-cell engager: Enhancing approved T cell engager therapies to recruit both adaptive and innate immune arms for broader, more durable anti-tumor responses. Thinking beyond traditional Bispecifics by demonstrating how existing T cell engagers can be repurposed to drive wider immune activation without altering their structure or target affinity |
| 9 | John Mascola Chief Scientific Officer ModeX Therapeutics | 9.30 | Beyond Bispecifics: Tetraspecific T Cell Engagers to Enhance T Cell Activation & Overcome Tumor Heterogeneity & Antigen Loss A modular tetraspecific antibody platform to maximize the "power of multispecifics" and target complex diseases Combining CD3 and CD28 to mimic physiological T cell activation and promote optimal T cells survival and function Targeting two tumor antigens with one molecule to address tumor heterogeneity and minimize escape |
| | Vishal Khairnar Consultant Synaptimmune Therapeutics | 10.00 | Conditionally Active CD2 Co-Stimulatory DLL3 T-Cell Engager With Increased Efficacy & Minimal Cytokin Release Compared to Tarlatamab[™] in Small Cell Lung Cancer & Neuroendocrine Tumors Built in CD2 Costimulation in DLL3 T cell engager (TCE) enhances CD3 synapse formation and signaling to increase tumor killing in Small Cell Lung cancer (SLC) Conditional Activation of TCE only in presence of antigen engagement overcomes cytokine release syndrome associated with conventional TCE's Shows increased efficacy and safety for SLC tumor killing in-vitro and in humanized SLC tumor models compared to approved TCE, TarlatamabTM |
| | | 10.30 | Morning break |
| | Christoph Rader Chief Technology Officer Aethon Therapeutics | 11.00 | Companion T Cell Engagers for Covalent Inhibitors of Oncoproteins Blend Targeted & Immune Therapy to Overcome Cancer Cell Resistance Exploring at how the lack of durability of targeted therapy with covalent inhibitors of oncoproteins can be addressed with immune therapy - Looking at how MHC presentation of the covalently modified oncoprotein peptides on the cancer cell surface creates synthetic neoantigens (p*MHC) that can be targeted by antibodies with picomolar affinity and cross-HLA specificity Converting to p*MHC × CD3 T cell engagers to create a unique combination of targeted and immune therapy with the potential to impede cancer cell resistance Assessing preclinical proof-of-concept studies based on covalent inhibitors of oncoprotein KRAS G12C |

9



World Bispecific

September 9-11, 2025 | Boston, MA

Conference Day Two Thursday, September 11



WELCOME

EXPERT SPEAKERS

| Lev | verage Lessons fr | om Bis | pecific ADC Development to Improve Dual-Target Engagement |
|-----|--|--------------|---|
| | Jijun Dong Chief Scientific Officer Salubris Biotherapeutics | 11.30 | Engineering Bispecific & Bipartopic ADCs for Dual-Target Engagement: Overcoming Design Challenges Looking at the design of the Bipartopic JK06 to balance the target biology and payload safety and tolerability profile Navigating the challenges of designing Bispecific and Bipartopic ADCs – exploring how ADCs can be engineered to recognize the antigens for both target cells to then internalize in the cells Investigating a case study of dual targeting with a Bispecific ADC to takeaway learnings on overcoming design challenges with dual-target engagement |
| Ð | | 12.00 | Lunch Break |
| Exp | oloring Bispecific | Combi Tar | nation Therapies & Masking Techniques for Expanding Tumour get Landscape & Increased Specificity |
| | Giovanni Abbadessa Chief Medical Officer ModeX Therapeutics | 1.00 | From Bispecifics to Tetraspecifics: Multiple Targets, One Drug Bi- vs Tri- vs Tetra-specific Antibodies Tri-specifics can physiologically activate T cells and be well tolerated (eg HER2-CD3-CD28) Tetra-specifics can tackle antigen heterogeneity and loss, while physiologically activating T cells |
| | Rajkumar Ganesan Executive Director, Oncology Third Arc Bio | 1.30 | Exploring Masking Technology to Enhance Specificity & Cytotoxic Activity of Bispecifics Overview of the masking technology and engineering approaches for enhanced tissue specificity of bispecifics Choice of optimal substrate specificity for tumor-associated protease mediated prodrug activation. In vitro safety assessments for reduced systemic toxicity for the design of next-generation cancer therapeutics |
| | Integrating Translational Feedback to Refine Bispecific Design & Function Across Development Stages | | |
| | Aung Naing Professor The University of Texas MD Anderson Cancer Center | 2.00 | Boundtable Discussion: Bridging Biology & Translation: Optimizing Bispecific Design Through Cross-Continuum Insight This roundtable will explore how bidirectional translational research can be more effectively used to inform bispecific drug development across discovery, preclinical, and clinical stages. Participants will discuss how to better integrate biological understanding within specific disease contexts, refine <i>in vitro</i> models to improve predictive value, and close mechanistic gaps through real-time feedback between clinical and nonclinical functions. The discussion will also consider how costimulatory pathways and immune modulators can be evaluated to fine-tune bispecific functionality and therapeutic outcomes How can we improve communication and alignment between translational, preclinical, and clinical teams during bispecific development? In what ways can <i>in vitro</i> design and validation be enhanced to more accurately predict <i>in vivo</i> pharmacology and safety? What are the biggest current gaps in mechanistic understanding of bispecifics that hinder clinical translation? How do we assess whether immune modulatory and costimulatory signals are functioning as expected in early development? What models or translational strategies have proven most effective in iterating bispecific designs for specific disease settings? |
| Ð | Aung Naing Professor The University of Texas MD Anderson Cancer Center | 3.00 | Chair's Closing Remarks |
| | | 3.15 | End of Conference Day Two |
| | | | |

10



REGISTER YOUR PLACE

AGENDA

Partner With Us



EXPERT SPEAKERS

AGEND/



Connect with Leading Bispecific Drug Developers to Fulfil **Your Business Development Goals**

The 16th World Bispecific Summit unites the leading minds driving the evolution of bispecific and multispecific antibody therapeutics. With cutting-edge insights into T-cell engagers, bispecific ADCs, autoimmune disease applications, and brand new target pairing like PD-1/VEGF, this is the definitive forum for showcasing how your solutions can support next-generation drug design, engineering, and development. Whether you offer advanced protein engineering tools, translational platforms, or clinical development capabilities, this is your opportunity to align with innovators tackling the most pressing efficacy, safety, and specificity challenges in bispecific antibody drug development.



Uncover the Key Industry Challenges

Gain first-hand insight into the technical and strategic hurdles that leading drug developer teams are facing. From antibody discovery bottlenecks to format optimization and clinical translation. By understanding their real-time challenges, you can tailor your offerings and align your capabilities to directly support their next-stage development needs.



Demonstrate your Expertise

Engage in focused, science-driven conversations with senior R&D leaders looking for trusted collaborators.



GET INVOLVED

11



Dylan Paul Senior Business Development Manager Tel: +1 617 455 4188 Email: sponsor@hansonwade.com

Raise your Brand

Position your brand in front of an

audience actively searching for

Awareness





PARTNER WITH US

2025 Partners



WELCOME

Lead Partner - Invenra

invenra

Invenra have developed an extensive and proprietary set of platform technologies to enable the discovery and development of novel therapies across a wide range of therapeutic targets. With an initial focus in oncology, Invenra and their partners have leveraged our platforms and are currently advancing pipelines of novel bi- and multi-specific antibody candidates that have demonstrated unparalleled combinatorial specificity and best-in-class potential in pre-clinical studies to date.

www.invenra.com

Program Partner - Alloy Therapeutics



Alloy help their ecosystem of partners and collaborators discover drugs by providing fully integrated services and offering access to foundational technologies. Alloy specialize in multiple modalities and take on challenging projects with confidence, backed by their years of experience and track record of success.

www.alloytx.com



Innovation Partner - BSP Pharmaceuticals

BSP Pharmaceuticals is a CDMO, technologically developed to meet needs of groundbreakers and specialized in manufacturing Oncology and Immunotherapy drug, including autoimmune disease, immunotherapy & CNS among others, with a specific focus on innovative compounds= as small and large molecules. With full containment facility, applying the most advanced and safe technologies, BSP can offer a wide range of services for Pre-Clinical, Clinical and Commercial supply in compliance with the highest Quality requirements.

www.bsppharmaceuticals.com



Innovation Partner - Nono Biosciences

Nona Biosciences is a Boston-based Biotech company specialized in fully human therapeutic antibody technology. Our proprietary Harbour Mice® technology are fully human transgenic mice platforms for either conventional fully human antibody (H2L2) or heavy chain only (HCAb) antibody discovery, engineering, and development. The HCAb platform is fully optimized and clinically validated with global patented protection.

www.nonabio.com

12

Exhibition Partner - Biocytogen Boston Corp

Leveraging proprietary, high-efficiency gene-editing technologies, Biocytogen is a global leader in animal and cell model generation for preclinical research. Through BioMice[™], we offer thousands of off-the-shelf drug-targeted humanized models, providing ready-to-use solutions for drug efficacy, safety, and mechanistic studies. Beyond model generation, Biocytogen accelerates global drug discovery with comprehensive preclinical pharmacology and gene-editing services, driving breakthroughs in oncology, immunology, and beyond.

www.biocytogen.com

GET INVOLVED



Dylan Paul Senior Business Development Manager Tel: +1 617 455 4188 Email: sponsor@hansonwade.com



hansonwade

2025 Partners

September 9-11, 2025 | Boston, MA

Exhibition Partner - Biointron

Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, optimization, and expression services for global biotech and pharmaceutical companies. Biointron holds a leading position in the antibody expression industry. From gene sequence to purified antibodies, it only takes 2 weeks. Biointron have delivered over ten thousand of recombinant antibodies for 2,000+ biotech and pharma companies worldwide.

www.biointron.com

Exhibition Partner - Creative BioLabs



🖉 BIOINTRON

Technical advancement has always been a focus of Creative Biolabs, which, sustained by seasoned scientists and cutting-edge methodologies, provides technical support for global customers in the academic and industrial sectors with market-pioneering solutions especially for bispecific antibody (BsAb) discovery, covering BsAb antibody design, purification, engineering, analysis, as well as top-tier BsAb products such as appended IgGs, tandem scFv, bispecific IgGs, diabody, and minibody. Featured and exclusive platforms incorporating hybridoma, chemical conjugation, and genetic engineering are the driving force behind the success of assorted projects.

www.creative-biolabs.com

Exhibition Partner - Nicoya Lifesciences

«nicoya

Nicoya is a Canadian life sciences tools company specializing in innovative biosensor technology for the academic, biotechnology and pharmaceutical sectors. Their Alto[™] digital SPR platform is the first of its kind, integrating digital microfluidics and surface plasmon resonance technologies to create the world's friendliest SPR system. With a flexible 16-channel design, 2 µL sample requirements, automated sample preparation, and one-click analysis, Alto takes you from sample to answer within hours and equips your team with high-quality data to accelerate biotherapeutic development.

www.nicoyalife.com

Exhibition Partner - OmniAb



OmniAb's discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of nextgeneration therapeutics. At the heart of the OmniAb platform is the Biological Intelligence[™] (BI) of our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic® (transgenic rat) and Amnicolid® (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur[™] features unique structural attributes of cow antibodies for complex targets.

www.omniab.com



Exhibition Partner - Sanyou Bio

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS", to accomplish the mission "to make the R&D easy for innovative biologics".

www.sanyoubio.com

info@hansonwade.com

in World Bispecific Forum

GET INVOLVED

+1 617 455 4188

🕀 www.bispecific.com

13



Dylan Paul Senior Business Development Manager Tel: +1 617 455 4188 Email: sponsor@hansonwade.com



Ready to Register?

3 Easy Ways to Book





DISCOVER how leading biopharma innovators are advancing bispecific T-cell engagers, ADCs, and autoimmune-targeting multispecifics through smarter engineering, strategic target selection, and novel immune-modulatory mechanisms



BUILD your understanding of the evolving challenges and priorities in bispecific drug development, spanning format optimization, toxicity mitigation, and translational predictability, to better align your solutions with what developers need most

ENGAGE with senior scientists, platform engineers, translational experts, and clinical strategists from leading biotech and pharma companies actively seeking the next generation of tools, technologies, and partnerships to accelerate multispecific drug development

| Drug Developer Pricing* | Register & Pay By Friday, 13 June | On the Door Price |
|--|-----------------------------------|-------------------|
| Conference + Seminar Day | \$3,297 (Save \$900) | \$4,197 |
| Conference Only | \$2,499 (Save \$500) | \$2,999 |
| Academic & Non-Profit Pricing** | Register & Pay By Friday, 13 June | On the Door Price |
| Conference + Seminar Day | \$2,697 (Save \$900) | \$3,597 |
| Conference Only | \$2,099 (Save \$500) | \$2,599 |
| Service & Solution Provider Pricing | Register & Pay By Friday, 13 June | On the Door Price |
| Conference + Seminar Day | \$4,197 (Save \$900) | \$5,097 |
| Conference Only | \$3,199 (Save \$500) | \$3,699 |

To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email info@hansonwade.com **To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts**

- 10% discount 2 Attendees
- 15% discount 3 Attendees
- 20% discount 4 + Attendees

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time. Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

| The Royal Sone 40 Edwin H Land Blvd, Cambridge, MA 02142, U |
|--|
| For further information or assistance, please visit: www.so royal-sonesta/ma/cambridge/royal-sone |

TERMS & CONDITIONS

14

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attrachees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time. Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Lid, Eastoastle House, 27/28 Eastoastle Street, London, W1W 8DH, United Kingdom AGEND/

WELCOME

EXPERT SPEAKERS





enue

sta Boston nited States nesta.com/ sta-boston